title: Mechanism of the hypotensive effect of a novel phenylpiperazine derivative, SGB-1534: antagonism at alpha 1-adrenergic and 5-HT2 receptors.
abstract: The present in vivo and in vitro experiment was designed to examine the hypotensive mechanisms of 3-[2-[4-(o-methoxyphenyl)-1-piperazinyl]ethyl]-2,4 (1H,3H)-quinazolinedione monohydrochloride (SGB-1534). The compound given orally significantly inhibited the pressor response to i.v. noradrenaline in rats and to 5-hydroxytryptamine (5-HT) in guinea-pigs but failed to block the pressor response to i.v. angiotensin II in rats. In pithed rats, SGB-1534 given i.v. had no effects on the prazosin-resistant part of the pressor effect of i.v. adrenaline, whereas it significantly inhibited the yohimbine-resistant part. In isolated guinea-pig aortae, SGB-1534 competitively inhibited the contractile response to noradrenaline with a pA2 value of 8.86, 6 times higher than prazosin. A combination of SGB-1534 with prazosin antagonized the noradrenaline effect as expected for a single class (alpha 1) of receptor. In isolated rabbit femoral arteries, SGB-1534 attenuated the contractile response to 5-HT with a pA2 value of 6.13, 400 times lower than ketanserin. A combination of SGB-1534 with ketanserin antagonized the 5-HT effect as expected for a single class (5-HT2) of receptor. In rat stomach fundus strips, SGB-1534 as well as ketanserin, even in a large dose, unlike methysergide, caused only slight inhibition of contractile response to 5-HT. These results indicate that SGB-1534 is a selective, competitive antagonist of the alpha 1-adrenoceptor and the 5-HT2 receptor, which may help to explain its antihypertensive properties.
authors.forename: J
authors.initials: J
authors.lastname: Aono
authors.forename: H
authors.initials: H
authors.lastname: Nabata
authors.forename: N
authors.initials: N
authors.lastname: Ishizuka
authors.forename: K
authors.initials: K
authors.lastname: Sakai
mesh_terms: D000317:Adrenergic alpha-Antagonists; D000758:Anesthesia; D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology*; D003655:Decerebrate State; D005748:Gastric Fundus / Q000187:drug effects; D006168:Guinea Pigs; D066298:In Vitro Techniques; D007650:Ketanserin; D008297:Male; D009119:Muscle Contraction / Q000187:drug effects; D009130:Muscle, Smooth / Q000187:drug effects; D009131:Muscle, Smooth, Vascular / Q000187:drug effects; D010880:Piperidines / Q000494:pharmacology; D011224:Prazosin / Q000494:pharmacology; D011799:Quinazolines / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains; D012702:Serotonin Antagonists
chemical_list: D000317:Adrenergic alpha-Antagonists; D000959:Antihypertensive Agents; D010880:Piperidines; D011799:Quinazolines; D012702:Serotonin Antagonists; C042712:SGB 1534; D007650:Ketanserin; D011224:Prazosin